Peter Bou Dib: How Factor IX Transformed Hemophilia B Treatment
Peter Bou Dib, Key Account Manager at Sino Biological Europe, shared a post on LinkedIn:
“Every day, thousands rely on a tiny but mighty protein to keep their blood flowing safely, Factor IX.
This protein, discovered from a young patient named Stephen Christmas, quietly plays a life-saving role in the complex dance of blood clotting.
Without Factor IX, people with Hemophilia B face constant risks of severe bleeding, impacting their daily lives and dreams.
Thanks to decades of research and innovation, treatments like recombinant Factor IX and emerging gene therapies offer hope and freedom.
Science continues to transform challenges into possibilities, turning a rare protein deficiency into a story of resilience and renewed life.
Here’s to the breakthroughs that rewrite what’s possible.
Want to learn more about proteome in under a minute every day?
Follow Five days, one play, one antigen each day!”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian